| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_244630447017dc0b8a917a82d7ad0036
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_76ab26596c5f45df79d217920da474e6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bd6ad2ba308307112ce6de3052427f51 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-86 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-567
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-557
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-00 |
| filingDate |
2004-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_34ac02deccee8580c58fc9c0c6074dce
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4771be0b0ca117b7879e765f04e0ab22 |
| publicationDate |
2005-01-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2005007868-A2 |
| titleOfInvention |
Controlled platelet activation to monitor therapy of adp antagonists |
| abstract |
A method is provided of determining whether an individual has reduced ability to form platelet thrombi due to inhibition of platelet activation initiation, signal transduction and/or GPIlb/IIIa blockade. A blood sample is obtained from the individual being assessed. The blood sample is mixed in combination with 1) an anticoagulant; 2) sufficient buffer to maintain the pH and salt concentration of the anticoagulated blood within a range suitable for platelet aggregation; 3) a platelet GPIIb/IIIa receptor ligand immobilized on a solid surface; 4) one or more agents to enhance a signal transduction pathway and 5) a receptor activator. The combination is incubated under conditions for agglutinating particles. Platelet-mediated agglutination is assessed in the agitated mixture. The absence of agglutination indicates that the individual has a reduced ability to form platelet thrombi. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2007298511-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8999243-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7595169-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3321680-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008137600-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8895259-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008137673-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7790362-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2500726-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2010526319-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2508892-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2508893-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102680523-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9341637-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2007298512-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2015093770-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8735163-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1885873-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1850134-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1850135-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2010526300-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9506938-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1885873-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9759730-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8574828-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8741873-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011008780-A1 |
| priorityDate |
2003-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |